Table 2.
Univariate and multivariate analysis of progression free survival (n=22).
| Variable | Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| B | Exp (B) (95% CI) | P | B | Exp (B) (95% CI) | P | |||
| LDH, U/L | -0666 | 0.514 (0.204-1.295) | 0.158 | -0.312 | 0.732 (0.075-7.169) | 0.789 | ||
| CEA, ng/ml | -1.203 | 0.300 (0.082-1.096) | 0.085 | -1.064 | 0.345 (0.024-4.948) | 0.434 | ||
| Metastatic sites involved | 0.931 | 2.538 (0.936-6.884) | 0.067 | 0.707 | 2.027 (0.331-12.420) | 0.445 | ||
| Histological type | 1.874 | 6.512 (1.047-40.524) | 0.045 | 1.168 | 3.216 (0.084-122.749) | 0.530 | ||
| Differentiation | -1.008 | 0.365 (0.128-1.039) | 0.059 | -0.615 | 0.541 (0.095-3.069) | 0.488 | ||
| Mean VAF | -0.120 | 0.887 (0.321-2.452) | 0.887 | -0.801 | 0.449 (0.056-3.574) | 0.449 | ||
| Site of primary lesion | 0.382 | 1.466 (0.418-5.38) | 0.550 | -0.173 | 0.841 (0.087-8.124) | 0.881 | ||
| Primary tumor resection | -0.119 | 0.888 (0.366-2.152) | 0.793 | -0.013 | 0.987 (0.153-6.362) | 0.989 | ||
| RAS status at baseline | 2.029 | 7.610 (2.093-27.669) | 0.002 | 0.921 | 0.987 (0.153-8.362) | 0.443 | ||
LDH, lactate dehydrogenase; CEA, carcinoembryonic antigen.